Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan
Background: Methotrexate is the first-line drug for treating patients with juvenile idiopathic arthritis (JIA). If it is ineffective or intolerable, prescription of genetically engineered biopharmaceuticals is indicated. Objective: The study was aimed at assessing effectiveness and safety of genetic...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2016-02-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/1367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849395890565939200 |
|---|---|
| author | V. A. Maliyevskiy O. A. Maliyevskiy G. R. Gareyeva L. S. Nazarova A. A. Khasanova A. Z. Nuriyakhmetova D. D. Prolygina |
| author_facet | V. A. Maliyevskiy O. A. Maliyevskiy G. R. Gareyeva L. S. Nazarova A. A. Khasanova A. Z. Nuriyakhmetova D. D. Prolygina |
| author_sort | V. A. Maliyevskiy |
| collection | DOAJ |
| description | Background: Methotrexate is the first-line drug for treating patients with juvenile idiopathic arthritis (JIA). If it is ineffective or intolerable, prescription of genetically engineered biopharmaceuticals is indicated. Objective: The study was aimed at assessing effectiveness and safety of genetically engineered biopharmaceutical adalimumab for treating children with JIA. Methods: A retrospective cohort study was conducted to analyze results of treating patients with JIA aged 2–17 years. Adalimumab would be prescribed biweekly in the dose of 24 mg/m2 (body surface) subcutaneously (if body weight is under 30 kg) or in the dose of 40 mg/m2 (if body weight is > 30 kg). Effectiveness and safety would be assessed after 4–12–24–48–96 weeks. Results: We analyzed treatment results of 17 patients (15 children with active joint syndrome, 2 — with active uveitis). All patients with active joint syndrome had been receiving adalimumab for 12 weeks, 12 patients — for 24 weeks, 8 — for 48 weeks, 5 — for 96 weeks. 30/50/70% improvement in terms of the ACRpedi criteria was observed in 15/11/4 children after 4 weeks, after 12 weeks — in 15/13/11 patients, after 48 weeks — in 7/6/6 patients. The status of inactive disease was established in 5 patients (33%) after 12 weeks, after 24 weeks — in 9 children (75%), after 48 weeks — in 7 children (70%), after 96 weeks — in 4 (80%) children. Active uveitis was terminated in all 5 patients with signs of eye damage in the treatment onset. 1 patient suffered from exacerbation of the disease after 48 weeks of therapy; the drug was withdrawn. Tubercular infection without local manifestations was established in 1 patient after 96 weeks (positive Mantoux test, papule — 10 mm). Adalimumab injection was terminated for the period of chemotherapy. Conclusion: Adalimumab has a sufficiently high effectiveness and safety for long-term (up to 2 years) treatment of children with JIA. |
| format | Article |
| id | doaj-art-5874dc5ac9c04eceb9c035b5d516ade4 |
| institution | Kabale University |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2016-02-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-5874dc5ac9c04eceb9c035b5d516ade42025-08-20T03:39:29ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892016-02-0112664565010.15690/pf.v12i6.14871359Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of BashkortostanV. A. Maliyevskiy0O. A. Maliyevskiy1G. R. Gareyeva2L. S. Nazarova3A. A. Khasanova4A. Z. Nuriyakhmetova5D. D. Prolygina6Bashkir State Medical University, Ufa, Russian FederationBashkir State Medical University, Ufa, Russian FederationBashkir State Medical University, Ufa, Russian FederationBashkir State Medical University, Ufa, Russian FederationRepublican Clinical Pediatric Hospital, Ufa, Russian FederationRepublican Clinical Pediatric Hospital, Ufa, Russian FederationRepublican Clinical Pediatric Hospital, Ufa, Russian FederationBackground: Methotrexate is the first-line drug for treating patients with juvenile idiopathic arthritis (JIA). If it is ineffective or intolerable, prescription of genetically engineered biopharmaceuticals is indicated. Objective: The study was aimed at assessing effectiveness and safety of genetically engineered biopharmaceutical adalimumab for treating children with JIA. Methods: A retrospective cohort study was conducted to analyze results of treating patients with JIA aged 2–17 years. Adalimumab would be prescribed biweekly in the dose of 24 mg/m2 (body surface) subcutaneously (if body weight is under 30 kg) or in the dose of 40 mg/m2 (if body weight is > 30 kg). Effectiveness and safety would be assessed after 4–12–24–48–96 weeks. Results: We analyzed treatment results of 17 patients (15 children with active joint syndrome, 2 — with active uveitis). All patients with active joint syndrome had been receiving adalimumab for 12 weeks, 12 patients — for 24 weeks, 8 — for 48 weeks, 5 — for 96 weeks. 30/50/70% improvement in terms of the ACRpedi criteria was observed in 15/11/4 children after 4 weeks, after 12 weeks — in 15/13/11 patients, after 48 weeks — in 7/6/6 patients. The status of inactive disease was established in 5 patients (33%) after 12 weeks, after 24 weeks — in 9 children (75%), after 48 weeks — in 7 children (70%), after 96 weeks — in 4 (80%) children. Active uveitis was terminated in all 5 patients with signs of eye damage in the treatment onset. 1 patient suffered from exacerbation of the disease after 48 weeks of therapy; the drug was withdrawn. Tubercular infection without local manifestations was established in 1 patient after 96 weeks (positive Mantoux test, papule — 10 mm). Adalimumab injection was terminated for the period of chemotherapy. Conclusion: Adalimumab has a sufficiently high effectiveness and safety for long-term (up to 2 years) treatment of children with JIA.https://www.pedpharma.ru/jour/article/view/1367childrenjuvenile idiopathic arthritisgenetically engineered biopharmaceuticalsadalimumab |
| spellingShingle | V. A. Maliyevskiy O. A. Maliyevskiy G. R. Gareyeva L. S. Nazarova A. A. Khasanova A. Z. Nuriyakhmetova D. D. Prolygina Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan Педиатрическая фармакология children juvenile idiopathic arthritis genetically engineered biopharmaceuticals adalimumab |
| title | Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan |
| title_full | Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan |
| title_fullStr | Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan |
| title_full_unstemmed | Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan |
| title_short | Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan |
| title_sort | retrospective cohort study of effectiveness and safety of adalimumab use in children with juvenile idiopathic arthritis in the republic of bashkortostan |
| topic | children juvenile idiopathic arthritis genetically engineered biopharmaceuticals adalimumab |
| url | https://www.pedpharma.ru/jour/article/view/1367 |
| work_keys_str_mv | AT vamaliyevskiy retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan AT oamaliyevskiy retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan AT grgareyeva retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan AT lsnazarova retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan AT aakhasanova retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan AT aznuriyakhmetova retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan AT ddprolygina retrospectivecohortstudyofeffectivenessandsafetyofadalimumabuseinchildrenwithjuvenileidiopathicarthritisintherepublicofbashkortostan |